Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506.
Most recipients of simultaneous pancreas-kidney transplants experience acute rejection in the early postoperative course. We report our experience with four recipients of simultaneous pancreas-kidney transplants with acute rejection who were effectively treated with the combination of intravenous and oral FK506 therapy. This spared these patients an extra course of monoclonal or polyclonal antibody.
Ciancio
G
G
Department of Surgery, University of Miami School of Medicine, Miami Veterans Administration Medical Center, Florida 33101, USA.
Burke
G W
GW
Roth
D
D
Miller
J
J
D000284:Administration, Oral; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D016030:Kidney Transplantation; D008297:Male; D016035:Pancreas Transplantation; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016559:Tacrolimus